Sign In
Buy XVIPF
Xvivo Perfusion AB Earnings Calls
| Release date | Apr 24, 2026 |
| EPS estimate | $0.0993 |
| EPS actual | $0.124 |
| EPS Surprise | 24.48% |
| Revenue estimate | 24.814M |
| Revenue actual | 25.353M |
| Revenue Surprise | 2.17% |
| Release date | Jan 27, 2026 |
| EPS estimate | $0.0740 |
| EPS actual | $0.113 |
| EPS Surprise | 52.82% |
| Revenue estimate | 23.163M |
| Revenue actual | 24.453M |
| Revenue Surprise | 5.57% |
| Release date | Oct 23, 2025 |
| EPS estimate | $0.0462 |
| EPS actual | $0.0272 |
| EPS Surprise | -41.17% |
| Revenue estimate | 214.896M |
| Revenue actual | 20.015M |
| Revenue Surprise | -90.69% |
| Release date | Jul 11, 2025 |
| EPS estimate | $0.0649 |
| EPS actual | $0.0052 |
| EPS Surprise | -91.98% |
| Revenue estimate | 203.892M |
| Revenue actual | 18.63M |
| Revenue Surprise | -90.86% |
Last 4 Quarters for Xvivo Perfusion AB
Below you can see how XVIPF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 11, 2025 |
| Price on release | $30.95 |
| EPS estimate | $0.0649 |
| EPS actual | $0.0052 |
| EPS surprise | -91.98% |
| Date | Price |
|---|---|
| Jul 07, 2025 | $30.88 |
| Jul 08, 2025 | $30.88 |
| Jul 09, 2025 | $30.50 |
| Jul 10, 2025 | $30.95 |
| Jul 11, 2025 | $30.95 |
| Jul 14, 2025 | $22.82 |
| Jul 15, 2025 | $23.50 |
| Jul 16, 2025 | $23.50 |
| Jul 17, 2025 | $21.95 |
| 4 days before | 0.227% |
| 4 days after | -29.10% |
| On release day | -26.27% |
| Change in period | -28.93% |
| Release date | Oct 23, 2025 |
| Price on release | $16.98 |
| EPS estimate | $0.0462 |
| EPS actual | $0.0272 |
| EPS surprise | -41.17% |
| Date | Price |
|---|---|
| Oct 17, 2025 | $19.00 |
| Oct 20, 2025 | $16.98 |
| Oct 21, 2025 | $16.98 |
| Oct 22, 2025 | $16.98 |
| Oct 23, 2025 | $16.98 |
| Oct 24, 2025 | $19.00 |
| Oct 27, 2025 | $16.98 |
| Oct 28, 2025 | $16.98 |
| Oct 29, 2025 | $16.98 |
| 4 days before | -10.66% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | -10.66% |
| Release date | Jan 27, 2026 |
| Price on release | $24.77 |
| EPS estimate | $0.0740 |
| EPS actual | $0.113 |
| EPS surprise | 52.82% |
| Date | Price |
|---|---|
| Jan 21, 2026 | $23.25 |
| Jan 22, 2026 | $23.25 |
| Jan 23, 2026 | $23.25 |
| Jan 26, 2026 | $23.25 |
| Jan 27, 2026 | $24.77 |
| Jan 28, 2026 | $24.77 |
| Jan 29, 2026 | $24.77 |
| Jan 30, 2026 | $25.49 |
| Feb 02, 2026 | $24.15 |
| 4 days before | 6.54% |
| 4 days after | -2.50% |
| On release day | 0% |
| Change in period | 3.87% |
| Release date | Apr 24, 2026 |
| Price on release | $22.81 |
| EPS estimate | $0.0993 |
| EPS actual | $0.124 |
| EPS surprise | 24.48% |
| Date | Price |
|---|---|
| Apr 20, 2026 | $22.81 |
| Apr 21, 2026 | $22.81 |
| Apr 22, 2026 | $22.81 |
| Apr 23, 2026 | $22.81 |
| Apr 24, 2026 | $22.81 |
| Apr 27, 2026 | $22.81 |
| Apr 28, 2026 | $22.81 |
| Apr 29, 2026 | $22.81 |
| Apr 30, 2026 | $22.81 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Xvivo Perfusion AB Earnings Call Transcript Summary of Q1 2026
Key investor takeaways: XVIVO reported a strong Q1 2026 with 23% organic revenue growth (18% excluding U.S. CAP trial revenue), record sales in thoracic (SEK 160m) and continued momentum in abdominal (SEK 66m) and services (SEK 60m). EVLP (lung) consumables grew strongly (EVLP disposables +56%) supported by a successful OPO EVLP hub pilot and increased field presence in the U.S. The U.S. PRESERVE heart trial met predefined efficacy and safety endpoints (low severe PGD) and XVIVO plans to submit the regulatory dossier to the FDA during the summer; CE-marking for aspects of the heart product is in progress and compassionate-use sales in Europe and strong uptake in Australia/New Zealand continue. Kidney sales were a standout in abdominal (+63% in local currency). Flowhawk software grew +62% and is now used by 6 of the 10 largest U.S. transplant programs. Profitability: gross margin overall 71%, EBIT 13% and EBITDA 21% (24% excluding SEK 7m nonrecurring heart go‑to‑market costs). XVIVO generated positive operating cash flow for the second consecutive quarter and ended Q1 with SEK 308m in cash. Management reiterated focus on expanding U.S. commercial footprint, OPO rollouts, pursuing CE and FDA approvals (heart, liver regulatory pathway assessment), and scaling service/organ‑recovery capacity to convert backlog into growth.
